CompletedNo phase
Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status
Key facts
- Who runs it
- Medical University of Graz
- Where
- Austria1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 40 people, planned
- Started
- 3 Jan 2017
- Ended
- 31 Dec 2024
- Type of study
- Observational
- Treatments tested
- Human albumin
- Record updated
- 6 March 2025
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age >18 years
- Routine indication for albumin infusion
- Informed consent
Who cannot take part
- Malignant ascites
- Nephrotic syndrome
- Albumin infusion >80g within the last 48 hours
- Presence of hepatocellular carcinoma or advanced extrahepatic neoplasia
- Pregnancy, lactation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to investigate the effect of albumin infusion on oxidative albumin modification, on plasma thiol status and on albumin binding capacity for DS in patients who routinely receive albumin infusion for various indications and to relate these findings with neurohumoral parameters, bacterial products such as endotoxin, and neutrophil function
The group in the trial
- Albumin infusion
Patients with decompensated cirrhosis and an indication for routine human albumin infusion
Treatment: Human albumin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 6 March 2025